 |
2 Diseases |  |
3 Trials |
|
3 Trials |  |
14 News |  |
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion date: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Mar 6, 2024
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
P1 data, Journal: Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. (Pubmed Central) - Mar 2, 2023
The administration of IL12 DNA along with a hepatitis C viral antigen DNA vaccine enhanced the HCV-specific immune responses induced by the vaccine in individuals with chronic hepatitis C, an important cause of hepatocellular carcinoma. IL12 could be an effective adjuvant in vaccines targeting HCV and other oncogenic viruses.
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
P1 data, Journal: Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. (Pubmed Central) - Dec 8, 2022
The addition of 1.0 mg of IL-12 DNA provided the best enhancement of immune responses. The vaccine regimen had little effect on controlling HCV viremia.
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 5, 2020
P1, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The vaccine regimen had little effect on controlling HCV viremia. Recruiting --> Active, not recruiting
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment open: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Jun 6, 2018
P1, N=32, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Recruiting
- INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial suspension: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 5, 2018
P1, N=32, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | INO-8000 / Inovio
Trial completion: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Aug 7, 2017
P1, N=18, Completed, Sponsor: GeneOne Life Science, Inc.
Recruiting --> Suspended Active, not recruiting --> Completed
- INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment open: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Aug 17, 2016
P1, N=32, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Jul 5, 2016
P1, N=32, Recruiting, Sponsor: Mayo Clinic
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - May 13, 2016
P1, N=32, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1/2 trial: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 17, 2015
P1/2, N=116, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- INO-8000 / Inovio
Enrollment closed: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Mar 14, 2015
P1, N=18, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- INO-8000 / Inovio
Enrollment open: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Jan 15, 2014
P1, N=18, Recruiting, Sponsor: VGX International, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | INO-8000 / Inovio
New P1 trial: VGX-6150-01: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (clinicaltrials.gov) - Jan 1, 2014
P1, N=18, Recruiting, Sponsor: VGX International, Inc.